Literature DB >> 23381597

C-reactive protein in bladder cancer: where do we stand?

Georgios Gakis, Arnulf Stenzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23381597     DOI： 10.1038/nrurol.2011.145-c1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

Review 1.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

2.  Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.

Authors:  Ganesh V Raj; Saumil Karavadia; Bruce Schlomer; Yull Arriaga; Yair Lotan; Arthur Sagalowsky; Eugene Frenkel
Journal:  Cancer       Date:  2010-09-09       Impact factor: 6.860

Review 3.  Current status of molecular markers for prognostication and outcome in invasive bladder cancer.

Authors:  Georgios Gakis; Christian Schwentner; Tilman Todenhöfer; Arnulf Stenzl
Journal:  BJU Int       Date:  2012-01-11       Impact factor: 5.588

4.  Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.

Authors:  Georgios Gakis; Tilman Todenhöfer; Markus Renninger; David Schilling; Karl-Dietrich Sievert; Christian Schwentner; Arnulf Stenzl
Journal:  BJU Int       Date:  2011-04-20       Impact factor: 5.588

Review 5.  C-reactive protein as a biomarker for urological cancers.

Authors:  Kazutaka Saito; Kazunori Kihara
Journal:  Nat Rev Urol       Date:  2011-10-25       Impact factor: 14.432

6.  Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach.

Authors:  Ajjai S Alva; Christopher T Tallman; Chang He; Maha H Hussain; Khaled Hafez; James E Montie; David C Smith; Alon Z Weizer; David Wood; Cheryl T Lee
Journal:  Cancer       Date:  2011-05-19       Impact factor: 6.860

7.  Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder.

Authors:  Peter U Ardelt; Burkhard Kneitz; Patrick Adam; Cora Reiss; Arkadius Kocot; Joachim Fensterle; Limor Chen; Renata Pasqualini; Wadih Arap; Elmar W Gerharz; Hubertus Riedmiller
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

8.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

Review 9.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962
  9 in total
  1 in total

1.  The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

Authors:  Richard M Bambury; David J Benjamin; Joshua L Chaim; Emily C Zabor; John Sullivan; Ilana R Garcia-Grossman; Ashley M Regazzi; Irina Ostrovnaya; Aryln Apollo; Han Xiao; Martin H Voss; Gopa Iyer; Dean F Bajorin; Jonathan E Rosenberg
Journal:  Oncologist       Date:  2015-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.